CTTC
-
VISE symposium explores interoperative fluorescence to light up tumors
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 18, 2017
-
BME PhD shifts to sepsis cure after dramatic end to pro cycling career
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreNov. 3, 2017
-
Vanderbilt Ph.D.’s new company provides researchers ‘X-ray’ on cellular processes
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreNov. 6, 2015
-
Engineers lead 6 of 10 ‘cool inventions’ of 2014: CTTC
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreJan. 16, 2015
-
Engineering shares Vanderbilt space at Nashville Entrepreneur Center
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreJul. 10, 2013
-
April 10 Boot Camp for aspiring Vanderbilt entrepreneurs
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreMar. 20, 2013